A Phase II Study of Stereotactic Radiosurgery for People with Small Cell Lung Cancer that Spread to the Brain


Full Title

A Single Arm Phase II Study Assessing Efficacy of Stereotactic Radiosurgery (SRS) for Brain Metastasis (BM) from Small Cell Lung Cancer (SCLC)


The purpose of this study is to assess stereotactic radiosurgery (SRS) to treat people with small cell lung cancer (SCLC) who have been newly diagnosed with brain metastases (cancer that spread to the brain). SRS specifically targets a very small area of the body. By targeting the part of the brain where the cancer has spread, SRS may shrink the cancer without damaging healthy brain tissue.

People with brain metastases from SCLC usually receive radiation therapy to their entire brain first, and may receive SRS if new brain metastases appear later. Researchers are doing this study to see if SRS is effective for people with a new diagnosis of brain metastases from SCLC.

Who Can Join

To be eligible for this study, patients must meet several requirements, including:

  • Participants must have brain metastases from SCLC that have not yet been treated with radiation therapy.
  • Patients must be able to walk and do routine activities for more than half of their normal waking hours.
  • This study is for people age 18 and older.


For more information and to ask about eligibility for this study, please contact the office of Dr. Luke Pike at 201-775-7604.




Phase II (phase 2)

Disease Status

Newly Diagnosed & Relapsed/Refractory



ClinicalTrials.gov ID